IL86650A0 - Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane - Google Patents

Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Info

Publication number
IL86650A0
IL86650A0 IL86650A IL8665088A IL86650A0 IL 86650 A0 IL86650 A0 IL 86650A0 IL 86650 A IL86650 A IL 86650A IL 8665088 A IL8665088 A IL 8665088A IL 86650 A0 IL86650 A0 IL 86650A0
Authority
IL
Israel
Prior art keywords
cells
liposomes
animal derived
membrane
derived cells
Prior art date
Application number
IL86650A
Other languages
English (en)
Original Assignee
Biophor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL86650(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biophor Corp filed Critical Biophor Corp
Priority to IL10569288A priority Critical patent/IL105692A/en
Publication of IL86650A0 publication Critical patent/IL86650A0/xx
Priority to IL105692A priority patent/IL105692A0/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
IL86650A 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane IL86650A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL10569288A IL105692A (en) 1987-06-30 1988-06-07 Liposomes to which a membrane has been inserted angiotic protein
IL105692A IL105692A0 (en) 1987-06-30 1993-05-13 Liposomes having an antigenic protein incorporated into their membranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
IL86650A0 true IL86650A0 (en) 1988-11-30

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86650A IL86650A0 (en) 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Country Status (9)

Country Link
US (1) US5677176A (fr)
EP (1) EP0298280B1 (fr)
JP (2) JP2728166B2 (fr)
AT (1) ATE114476T1 (fr)
AU (2) AU1821988A (fr)
CA (1) CA1327332C (fr)
DE (1) DE3852221T2 (fr)
ES (1) ES2067457T3 (fr)
IL (1) IL86650A0 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
CA1327174C (fr) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion de proteines dans des membranes de cellules animales
JPH04502168A (ja) * 1988-12-22 1992-04-16 ザ　ダウ　ケミカル　カンパニー 複素環式ポリマーの改良合成方法
DK0555333T3 (da) * 1990-10-19 1996-04-29 Univ Florida Kunstige virushylstre
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DK0517986T3 (da) * 1991-06-14 1998-03-30 Europ Communities Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
WO1993018160A1 (fr) * 1992-03-11 1993-09-16 Kenneth Francis Prendergast Peptides de fusion anti-viraux
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
WO1994004677A1 (fr) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation de vesicules a membranes plasmatiques a cd4 comme agent therapeutique contre le sida
JPH08501451A (ja) * 1992-09-22 1996-02-20 ディーエヌエックス バイオセラピューティックス、インコーポレーテッド 異種移植臓器移植片の事前適応化、その他を目的とする膜間転移によるタンパク質の供給法
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
EP0773951B1 (fr) * 1994-07-15 1999-03-10 Biosearch Italia S.p.A. 5',5'-pyrophosphates de dinucleosides
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO2000029556A2 (fr) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
EP1921451A3 (fr) * 2001-05-22 2008-05-28 Cygene, Inc. Analyses induites par complément pour procédés in vivo et in vitro
EP1442305B1 (fr) * 2001-10-16 2009-09-30 Kode Biotech Limited Regulations de la sensibilite pour serologie sanguine elaborees a partir de cellules modifiees
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20120034157A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
CN102712503A (zh) 2009-10-08 2012-10-03 大冢制药株式会社 用于治疗恶性肿瘤的免疫活性血液灌注过滤器
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
JP6735233B2 (ja) 2014-04-01 2020-08-05 ルビウス セラピューティクス， インコーポレイテッド 免疫調節方法及び組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
US5677176A (en) 1997-10-14
EP0298280A2 (fr) 1989-01-11
EP0298280A3 (en) 1990-05-02
DE3852221T2 (de) 1995-04-06
JP2825804B2 (ja) 1998-11-18
ATE114476T1 (de) 1994-12-15
DE3852221D1 (de) 1995-01-12
AU662154B2 (en) 1995-08-24
ES2067457T3 (es) 1995-04-01
JP2728166B2 (ja) 1998-03-18
AU1821988A (en) 1989-04-27
AU1942692A (en) 1992-09-24
JPH01124382A (ja) 1989-05-17
JPH1072368A (ja) 1998-03-17
EP0298280B1 (fr) 1994-11-30
CA1327332C (fr) 1994-03-01

Similar Documents

Publication Publication Date Title
IL86650A0 (en) Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
Zaremba et al. Assembly polypeptides from coated vesicles mediate reassembly of unique clathrin coats.
Schwartz et al. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein
Masucci et al. Effect of interferon-α1 from E. coli on some cell functions
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
EP0158277A3 (fr) Préparations implantables à libération contrôlée de peptides régulateurs et procédé pour leur fabrication
EP0370458A3 (fr) Antigènes à partir d'ADN synthétique dérivé du virus de l'immunodéficience humaine (HIV-1) recombinant
ATE199096T1 (de) Il-11 aus säugetier
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
GR3007031T3 (fr)
Cerny et al. CD4+ T cells in murine acquired immunodeficiency syndrome: evidence for an intrinsic defect in the proliferative response to soluble antigen
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
Gee et al. Differences between Syrian hamster strains in natural killer cell activity induced by infection with Pichinde virus
Bhardwaj et al. The processing and presentation of mycobacterial antigens by human monocytes
IL86675A (en) Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
EP0283443A3 (en) Process for extracting membrane antigens having immunogenic properties from human neoplastic cells and products thereby obtained
Dieleman et al. Acquired Zwa antigen on Zwa negative platelets demonstrated by western blotting
Marušić et al. Involvement of Mhc loci in immune responses that are not Ir-gene-controlled
Powell et al. Identification of SIV/SMM viral proteins that induce T cell response in experimentally infected rhesus macaques and naturally infected sooty mangabeys by the cellular western blot assay
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
Hale et al. Elicitation of anti-H-2 cytotoxic T lymphocytes with antigen-modified H-2 negative stimulator cells.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees